5.1 Purpose and Scope
This policy sets the minimum ethical requirements for any submission that involves humans, animals, sensitive data or materials, fieldwork, dual-use research, or high-risk methods. It applies to authors, editors, reviewers, and publisher staff across all journals we publish.
5.2 Core Principles
- Respect for persons, beneficence, and justice.
- Do no harm and minimize risk; risks must be reasonable in relation to anticipated benefits and scientific value.
- Independent ethical oversight prior to data collection when required.
- Transparency and accountability in reporting approvals, consent, and safeguards.
5.3 Human Participants (Non-clinical and Clinical)
- Ethics approval: Research involving human participants, identifiable data, or biological specimens must have prior approval from an independent ethics committee/IRB or documented exemption. Provide the committee name, approval number (if issued), and date.
- Informed consent: Obtain and document prospective, informed consent. For minimal-risk secondary analyses of properly de-identified data, justify any consent waiver granted by an ethics body.
- Privacy and confidentiality: De-identify data to accepted standards. Remove direct identifiers from text, figures, and supplementary files. Use controlled-access repositories for sensitive datasets.
- Vulnerable groups: Additional safeguards are required for children, older adults with impaired capacity, refugees, detainees, economically disadvantaged persons, and other groups with limited autonomy. Assent and guardian consent are required where applicable.
- Community and Indigenous data: Respect community review processes, data sovereignty principles, and benefit-sharing agreements. Clearly state permissions and governance arrangements.
5.4 Clinical Trials and Interventional Studies
- Prospective registration: Register trials in a WHO-recognized public registry before enrolling the first participant, and include the registration ID in the manuscript.
- Protocol and deviations: Provide access to protocols (or extended methods) and explain deviations from the protocol or pre-registration.
- Data monitoring and stopping rules: Report oversight arrangements (e.g., DSMB) and any stopping criteria.
- CONSORT-aligned reporting: Provide participant flow, allocation methods, blinding, outcomes, and harms.
5.5 Use of Human Biological Materials
- Consent scope: Ensure consent covers the specific use or clearly states broad consent terms for future research.
- Biobanks and MTAs: Describe governance, access conditions, Material Transfer Agreements, and anonymization level.
- Genomic data: Follow field norms for controlled access (e.g., dbGaP/ENA-EGA equivalents) and address re-identification risks.
5.6 Animal Research and Welfare
- Ethics approval: Animal studies require prior approval from an accredited committee. State the committee, approval identifier (if issued), and date.
- 3Rs—Replacement, Reduction, Refinement: Describe justification for animal use, humane endpoints, and steps to minimize suffering.
- Care and housing: Report species/strain, sex, age, housing conditions, anesthesia/analgesia, and euthanasia methods compliant with recognized guidelines.
- Wildlife and field studies: Confirm permits; describe capture/handling methods, release, and post-procedure monitoring.
- ARRIVE-aligned reporting: Provide group sizes, randomization, blinding, and statistical methods.
5.7 Fieldwork, Environmental, and Cultural Heritage Research
- Permits and permissions: Confirm and cite permits for sampling, excavation, export/import, and access to protected areas.
- Local collaboration and benefit sharing: Document equitable partnerships and capacity building where relevant.
- Environmental impact and biosafety: Describe mitigation for ecological disturbance, invasive species risks, or pollutant handling.
5.8 Dual-Use Research of Concern (DURC) and Biosecurity
- Risk identification: Authors must assess whether methods or results could be misused to cause significant harm (e.g., enhancing pathogen transmissibility or virulence, bypassing diagnostics, weaponization).
- Risk mitigation: Describe safeguards, facility level (e.g., BSL), and redaction or delayed release if needed.
- Compliance: Adhere to relevant laws on select agents, export controls, and shipping of biologicals. Editorial decisions may require modifications to methods or data sharing to reduce misuse risk.
5.9 High-Risk Methods and Hazardous Materials
- Biosafety/chemical safety: State facility certifications and training. Report incident-prevention measures for toxins, radiological sources, nanomaterials, or high-powered lasers.
- Engineering and cybersecurity: For systems with safety implications (e.g., autonomous robotics, critical infrastructure, offensive security tools), describe fail-safes, simulation-first testing, and coordinated disclosure practices.
5.10 Sensitive Data and Data Protection
- Data minimization: Collect only necessary data; avoid storing directly identifiable data unless essential and consented.
- Anonymization and access control: Use robust de-identification and access agreements; prefer controlled-access repositories for sensitive or rare-disease datasets.
- Cross-border transfer: Disclose mechanisms for lawful transfer where applicable (e.g., Standard Contractual Clauses); do not expose participants to legal or social harm.
5.11 AI/ML Using Human or Sensitive Data
- Dataset provenance: Disclose dataset sources, consent scope, licenses, and known biases.
- Fairness and safety: Report performance across subgroups and limitations; avoid deployment claims not supported by evidence.
- Reproducibility: Provide code, model cards, and evaluation protocols where legally and ethically permissible.
5.12 Deception, Waivers, and Debriefing
- Use of deception: Allowed only with prior ethics approval where no alternative exists and risk is minimal. Provide debriefing procedures and explain any waiver of debriefing.
- Consent waivers: Justify with reference to minimal risk and impracticability; include the approving body’s rationale.
5.13 Compensation and Undue Influence
- Payments to participants: Must be proportionate to time and inconvenience, not coercive, and disclosed in methods or ethics statements.
5.14 Incidental Findings and Duty of Care
- Clinical and non-clinical contexts: Describe procedures for managing incidental findings (e.g., genetic variants of clinical significance), including referral pathways where appropriate.
5.15 Images, Audio, and Identifiable Media
- Explicit consent: Required for publication of images, audio, or video that could identify participants, including partially obscured faces or distinctive tattoos/scars.
- Children: Obtain guardian consent and, where feasible, child assent. Avoid unnecessary identifiability.
5.16 Emergency, Conflict, and Disaster Settings
- Context-appropriate oversight: Where formal IRBs are unavailable, document community or humanitarian review processes and ethical safeguards.
- Do-no-harm priority: Extra caution for risks of reprisal, stigmatization, or surveillance; anonymize locations and traits when necessary.
5.17 What to Report in the Manuscript (Minimum Set)
- Name of ethics committee/IRB and approval number or exemption with justification.
- Consent procedures (including assent/guardian consent if applicable) and data-protection measures.
- Trial registration ID for interventional studies and access to protocol.
- Animal welfare approvals, permits, housing and care details, and humane endpoints.
- Fieldwork permits, export/import licenses, and benefit-sharing agreements where relevant.
- DURC/biosafety assessment and mitigation, including facility level and any justified redactions.
- Data/code availability statements with repository links and access conditions.
5.18 Editorial Screening and Verification
- Pre-review checks: Submissions are screened for ethics approvals, consent, trial registration, animal welfare statements, permits, and DURC flags.
- Conditional acceptance: Editors may require additional documentation (e.g., blank consent forms, permit copies, IACUC/IRB letters).
- Independent expertise: High-risk manuscripts may undergo specialist ethics or statistical review.
5.19 Non-Compliance and Remedial Actions
- Before publication: Manuscripts with inadequate ethics documentation may be rejected or held pending correction.
- After publication: Credible concerns trigger inquiry; editorial responses may include corrections, expressions of concern, or retractions. Institutions and funders may be notified where appropriate.
- Sanctions: Repeated or serious breaches may result in submission bans for a defined period.
5.20 Record-Keeping and Retention
- Authors should retain raw data, consent documents (or proof thereof), animal welfare logs, permits, and biosafety records for a period consistent with legal requirements and field norms.
- On reasonable request during editorial evaluation or post-publication audit, authors must provide documentation sufficient to verify compliance.
5.21 Accessibility and Plain-Language Ethics Statements
- Ethics statements must be written in clear, plain English. Avoid jargon; define acronyms at first use. Provide translations where this materially improves participant understanding or community engagement.